MediWound (NASDAQ:MDWD) Posts Earnings Results, Beats Estimates By $0.25 EPS

MediWound (NASDAQ:MDWD) released its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.25, RTT News reports. MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. During the same quarter in the prior year, the business posted ($0.19) earnings per share.

MediWound Stock Up 0.9 %

Shares of MDWD stock opened at $19.27 on Wednesday. The company’s fifty day simple moving average is $18.11 and its 200-day simple moving average is $17.60. The firm has a market cap of $207.85 million, a PE ratio of -6.64 and a beta of 0.82. MediWound has a 12 month low of $12.78 and a 12 month high of $24.00.

Wall Street Analyst Weigh In

MDWD has been the subject of a number of analyst reports. Craig Hallum initiated coverage on shares of MediWound in a report on Friday, February 28th. They set a “buy” rating and a $39.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of MediWound in a report on Friday, January 10th.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.